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ABSTRAcT
Introduction: The auto-inflammatory diseases (AID) are a heterogeneous group of multi-sys-
tem disorders of innate immunity dysregulation. MEFV gene has major role in AID. Aim: The 
aim of this study is to investigate the frequency of MEFV variant alleles in gout patients as an 
AID and their genotype-phenotype relationship. Methods: Total amount of 224 of the healthy 
people as a control group (113 male and 111 female) and 24 gouty arthritis patients (20 male 
and 4 female) entered this study. Blood samples screened for the 12 common pathogenic 
mutations according to manufacturer’s instructions. Results: The mean age of patients was 
54 years. MTP joint was the most involved joint (91.66%). Mutations were shown in 5 pa-
tients (20.83%) that were not different from healthy population (25%). Five patients carry 
one mutated MEFV allele, E148Q in 4 patients and V726A in 1 patient. Control group showed 
25% mutations as E148Q (18.3%), P369S (3.1%), V726A (2.2%), A744S (1.3%) respectively. 
The most common mutation detected in patients was E148Q (16.66%) and all of them were 
males. No significant and meaningful associations were detected between the MEFV gene 
mutations and gouty arthritis patients. Conclusion: There was not any correlation between 
MEFV gene mutations carriage with age, sex, the number of joint involvement and the course 
of disease in gouty arthritis. MEFV gene mutations were more frequent in men than women, 
but this is not statistically significant.
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1. INTRODUCTION
The auto-inflammatory disease, 
also known as periodic fever syn-
dromes, are a heterogeneous group 
of multi-systemic disorders of innate 
immunity characterized by fluctuat-
ing, self-limiting or irregularly recur-
ring episodes of fever and systemic 
inflammation (1, 2). FMF is the best-
known auto-inflammatory disease, 
nowadays novel ﬁndings provided 
information that leading to include 
gout into the spectrum auto-inflam-
matory diseases (3).
The MEFV gene is located on the 
short (p) arm of chromosome 16 at 
position 13.3(16p 13.3) (4). MEFV 
gene was predominantly expressed 
in granulocytes and monocytes (5), 
Both of which play major roles in 
the pathophysiology of inflamma-
tory disease at the acute phase (6).
MEFV gene encodes a protein called 
pyrin (or marenostrin) (7). Pyrin is 
involved in inflammations through 
altered apoptosis,caspase-1 activa-
tion, secretion of interleukin (IL)-1β 
and activation of the NF-κB pathway 
in innate immune system (8).
Several reports revealed that 
MEFV mutations were associated 
with vasculitis-related disorders as 
such Behcet disease, Henoch schon-
lein purpura (HSP), and polyarteritis 
nodosa (9, 10, 11), and associated 
with more severe course of some 
inflammatory diseases such as anky-
losing spondylitis (AS), inflammato-
ry bowel diseases (IBD), rheumatoid 
arthritis (RA) (12), suggesting that 
MEFV gene mutations contribute to 
the development of a broader spec-
trum of inflammation. Furthermore, 
it has been reported that MEFV mu-
tations might increase the baseline of 
inflammation, induced the develop-
ment of rheumatic diseases, and af-
fect the clinical course of inflamma-
tory disorders (13).
Gout is a clinical syndrome that 
occurs as an inflammatory response 
to increased concentration of uric 
acid and accumulation of monosodi-
um urate crystals (MSU) within the 
joint (14).
It is one of the most common in-
flammatory arthritis in the world 
that has been reported as 1–2 % in 
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men over the age of 30 and women over the age of 50 
years depending on ethnic variations. The incidence of 
gouty arthritis increases with the increasing age, and its 
prevalence is between 6 and 9 % after the age of 80 (15, 
16). In recent years, the role of the inflammasome com-
plex in the pathogenesis of the disease has been shown. 
Neutrophils are prominent mediators of the inflamma-
tory response in gout disease and IL-1 is an important 
factor that plays a major role in pathogenesis of gout. 
As for other pathogen crystals, the main mechanism of 
their inflammatory reaction is the activation of the intra-
cellular caspase-1-activating NLRP3 inﬂammasome. In 
recent studies, it was shown that NALP3 inﬂammasome 
complex has a significant role in acute inflammation in-
duced by MSU crystals (3, 17, 18).
Gouty arthritis and familial Mediterranean fever share 
some clinical and pathological features such as being 
classified as auto-inflammatory disease, associations 
with inflammasome, short-lived intermittent arthritis, 
and good response to colchicines and anti-interleukin-1 
treatment. 
2. AIM
The aim article is to investigate the frequency of MEFV 
variant alleles in gout patients as an AID and their geno-
type-phenotype relationship. 
3. METHODS
Patients
This is a retrospective study that include 24 gout pa-
tients who were diagnosed by the revised American 
College of Rheumatology (ACR) classification criteria 
(19). All patients were questioned for presence of FMF 
(Tel-Hashomer criteria) and positive family history for 
FMF (20). Patients with suspicious anamnesis and/or 
positive family history for FMF were excluded. Sex, age, 
number of gout attacks, history of nephrolithiasis and 
presence of tophus were also collected. All data were an-
alyzed by simple analytical test.
The study was approved by the local Ethics Commit-
tee of faculty of medicine and informed consent was ob-
tained from all the participants.
Control Group
On the basis of FMF frequency (0.1%) in Northwest of 
Iran, near to eastern Mediterranean area, we performed 
an investigation simultaneously to evaluate of MEFV 
gene mutations in normal and healthy population of this 
area. This study included 224 healthy people as a control 
group (113 male and 111 female).All of them were over 
50 years old, with negative history of FMF symptoms, in 
themselves and their first degree family.
MEFV gene mutation analysis
Blood samples were screened for the 12 common 
pathogenic variants (E148Q, P369S, F479L, I692del, 
M680I(G/C), M680I(G/A), M694V, M694I, K695R, 
V726A, A 744S, R 761H) by RDB assay (FMF Strip Assay, 
Vienna lab, Vienna, Austria) according to manufacturer’s 
instructions.
4. RESULTS
There were 224 of the healthy control group (113 male 
and 111 female) and 24 gouty arthritis patients (20 male 
and 4 female). The mean age of the patients was 54 years. 
The youngest patient was 31 years old and the oldest one 
was 80 years old. The median number of gouty attacks of 
the patients were 3 (1-10), 8.33% had renal stone histo-
ry. Duration of symptom in most of the patients was 10 
years. In the clinical evaluations of patients with gouty 
arthritis; first MTP joint involvement was observed in 
22 (91.66%), ankle arthritis in 3 (12.5%), knee arthritis in 
3(12.5%), elbow arthritis in 2 (8.33%) and heel arthritis in 
1 (4.1%) patients.
Five patients (20.83%) carry one mutated MEFV al-
lele, E148Q in 4 patients (16.66%) and V726A in 1 pa-
tient (Table 1). Control group showed 25% mutations, 
the most common variants were E148Q (18.3%), P369S 
(3.1%), V726A (2.2%), A744S (1.3%), respectively.
No correlation was found between MEFV gene muta-
tions carriage with age, sex, the number of joint involve-
ment and clinical signs of disease. MEFV gene mutations 
were more frequent in men (4 patients) than women, but 
this is not statistically significant.
5. DISCUSSION
Sari et al have investigated MEFV gene mutations 
frequency in patients with gouty arthritis and they 
found E148Q as the most common mutation in patients 
(22.7%), and the control group (24%) respectively. The 
presence of mutated variants did not show any associa-
tion with clinical features of gouty arthritis, and MEFV 
gene mutations role in its pathogenesis (21).
Similar study was published in the literature recently. 
Balkarli et al investigated the effects of MEFV variant 
alleles on the manifestations of gout in seventy-one pa-
tients diagnosed with gout. MEFV variant alleles were 
found in 24 (33.8 %) of the gout patients and in 13 (26 %) 
of the control subjects; the difference was not statistical-
ly significant. R202Q and K965R were the most common 
mutations among the both group. Although they found 
association between MEFV variant allele and severity of 
some clinical features, higher incidence of tophus and the 
higher number of attacks per year, they could not show a 
pathogenic role of these mutations in patients (22).
Karaarslan et al showed high carriage rate of MEFV 
gene mutations, in 93 gouty Patients which R202Q in 
19.3% compared with 102 healthy control group with 
E148Q in 10.7% and concluded that MEFV gene muta-
tions may play an important role in the pathogenesis of 
the disease and predisposing to the disease (23).
MEFV mutations, E148Q as the most common vari-
ants in patients with gouty arthritis in our study did not 
show meaningful difference from frequency of MEFV 
 Gouty arthritis patients
 N=24  Wide type  Mutations
 19  V726A (n=1)
 E148Q (n=4)
Table 1. distribution of the MEFV gene mutations in the gouty arthritis 
patients
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mutations in healthy population, 16.6% and 18.3% re-
spectively.
Not only MEFV gene variants did not show any associ-
ation with clinical features of gouty arthritis, but also the 
severity of gout did not show any difference between the 
patients with and without MEFV mutations.
To the best of our knowledge there is no other report 
regarding the association of MEFV mutations and gout 
in the literature.
The most common mutation detected in patients with 
gouty arthritis was heterozygous E148Q (16.66%). How-
ever, controversy exists regarding the role of the E148Q 
alleles in development of clinical feature of FMF, some 
reports emphasized the over-representation of E148Q in 
several inflammatory disorders (24). On the other hand 
the high prevalence of this mutation in normal popula-
tion( 18.3%) suggests that; this finding should be inter-
pret with caution.
6. CONCLUSION
This study has some limitations such as small sample 
size of 24 cases, however, despite of these limitations, 
unlike Karaarslan et al study, the results of this study do 
not provide a support for a major role of MEFV mutation 
in gouty arthritis patients.
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